SRPT:NGS-Sarepta Therapeutics Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 132.74

Change

+0.24 (+0.18)%

Market Cap

USD 1.99B

Volume

1.01M

Analyst Target

USD 193.38
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Sarepta Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of RNA-targeted therapeutics for the treatment of rare, infectious and other diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+3.24 (+0.68%)

USD 124.65B
REGN Regeneron Pharmaceuticals Inc

-1.12 (-0.11%)

USD 110.51B
MRNA Moderna Inc

-2.49 (-1.69%)

USD 57.87B
BNTX BioNTech SE

-1.91 (-1.95%)

USD 24.18B
ARGX argenx NV ADR

+5.84 (+1.53%)

USD 22.94B
ALNY Alnylam Pharmaceuticals Inc

+1.01 (+0.64%)

USD 20.12B
GMAB Genmab AS

-0.36 (-1.34%)

USD 18.17B
BGNE BeiGene Ltd

-1.73 (-1.03%)

USD 17.74B
RPRX Royalty Pharma Plc

N/A

USD 16.18B
BMRN Biomarin Pharmaceutical Inc

-0.31 (-0.37%)

USD 15.32B

ETFs Containing SRPT

PINK Simplify Exchange Traded .. 8.99 % 0.00 %

+0.08 (+-0.23%)

USD 0.12B
MSGR 6.12 % 0.00 %

N/A

N/A
XDNA:CA iShares Genomics Immunolo.. 5.63 % 0.00 %

N/A

CAD 5.15M
IDNA iShares Genomics Immunolo.. 4.85 % 0.00 %

-0.12 (-0.23%)

USD 0.14B
CURE:XETRA VanEck Genomics and Healt.. 4.54 % 0.00 %

+0.11 (+-0.23%)

USD 6.79M
GN0M:XETRA Global X Genomics & Biote.. 4.32 % 0.00 %

-0.01 (-0.23%)

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 4.32 % 0.00 %

N/A

USD 6.38M
CURG:LSE VanEck Genomics and Healt.. 4.28 % 0.00 %

-0.04 (-0.23%)

USD 6.79M
IBRN iShares Trust - iShares N.. 4.27 % 0.00 %

+0.13 (+-0.23%)

USD 3.84M
GNOG:LSE Global X Genomics & Biote.. 3.91 % 0.00 %

-0.02 (-0.23%)

USD 6.38M
CDNA:CA CI Bio-Revolution ETF 3.09 % 0.00 %

N/A

CAD 5.88M
ETLI:F Legal & General UCITS ETF.. 2.46 % 0.00 %

-0.04 (-0.23%)

USD 0.02B
ETLI:XETRA L&G Pharma Breakthrough U.. 2.46 % 0.00 %

-0.04 (-0.23%)

USD 0.02B
BIOT:SW L&G Pharma Breakthrough U.. 2.46 % 0.00 %

-0.08 (-0.23%)

N/A
BTEC Principal Healthcare Inno.. 2.36 % 0.42 %

+0.04 (+-0.23%)

USD 0.03B
W311:XETRA HAN-GINS Indxx Healthcare.. 1.51 % 0.00 %

-0.04 (-0.23%)

USD 0.02B
W311:F HAN-GINS Indxx Healthcare.. 1.51 % 0.00 %

-0.05 (-0.23%)

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 1.51 % 0.00 %

-0.05 (-0.23%)

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 1.51 % 0.00 %

-0.04 (-0.23%)

N/A
WELP:LSE HAN-GINS Indxx Healthcare.. 1.44 % 0.00 %

-5.25 (-0.23%)

USD 0.02B
WELL:LSE Hanetf Icav - Han-Gins He.. 1.44 % 0.00 %

-0.09 (-0.23%)

USD 0.02B
ISCG iShares Morningstar Small.. 0.55 % 0.00 %

-0.41 (-0.23%)

USD 0.55B
BTAL AGFiQ U.S. Market Neutral.. 0.45 % 0.00 %

-0.01 (-0.23%)

USD 0.23B
JKK iShares Morningstar Small.. 0.00 % 0.30 %

N/A

USD 0.55B
LABS 0.00 % 0.45 %

N/A

N/A
DWEQ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 37.65% 78% C+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 37.65% 78% C+ 88% B+
Trailing 12 Months  
Capital Gain -9.35% 59% D- 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.35% 59% D- 38% F
Trailing 5 Years  
Capital Gain 9.10% 74% C 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.10% 73% C 52% F
Average Annual (5 Year Horizon)  
Capital Gain 9.94% 67% D+ 69% C-
Dividend Return 9.94% 67% D+ 67% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 47.76% 59% D- 35% F
Risk Adjusted Return 20.81% 76% C+ 57% F
Market Capitalization 1.99B 98% N/A 94% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 315.48 5% 4%
Price/Book Ratio 13.43 11% 8%
Price / Cash Flow Ratio -25.00 95% 90%
Price/Free Cash Flow Ratio -24.82 96% 91%
Management Effectiveness  
Return on Equity 2.02% 95% 62%
Return on Invested Capital -14.09% 83% 37%
Return on Assets -1.89% 95% 49%
Debt to Equity Ratio 131.79% 14% 17%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.